Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192751 | 0.94 | MEN1 (0.52) | POLBKMT2AMEN1MTNR1ATRPV1 | |
| SCHEMBL4187107 | 0.91 | TRPV1 (0.50) | POLBKMT2AMEN1MTNR1ATRPV1 | |
| SCHEMBL4186899 | 0.90 | HDAC1 (0.56) | KMT2AMEN1NAMPTALDH1A1MAPT | |
| SCHEMBL4183434 | 0.86 | HDAC1 (0.47) | POLBKMT2AMEN1TRPV1ALDH1A1 | |
| SCHEMBL4183294 | 0.85 | ACHE (0.48) | POLBKMT2AMEN1MTNR1ATRPV1 | |
| SCHEMBL4195363 | 0.85 | HDAC1 (0.52) | TRPV1MAPTSMN1; SMN2 | |
| SCHEMBL4192122 | 0.85 | HDAC1 (0.47) | KMT2AMEN1TRPV1NAMPTMAPT | |
| SCHEMBL13653271 | 0.84 | ABCB1 (0.47) | KMT2AMEN1TRPV1ALDH1A1MAPT | |
| SCHEMBL4188501 | 0.84 | HDAC1 (0.50) | POLBKMT2AMEN1NAMPTALDH1A1 | |
| SCHEMBL4186856 | 0.82 | HDAC1 (0.44) | TRPV1NAMPTPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | POLB 1020/4885KMT2A 1662/4885MEN1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.